Introduction
In 1917, the first documented case of a strain of Drosophila characterized by notches at the ends of their wing blades was reported. These notches were caused by haploinsufficiency of an unknown gene, which was subsequently cloned in the mid-1980's and identified as the gene coding for the Drosophila transmembrane receptor Notch 1 . Notch orthologues have since been identified in numerous organisms including mammals. A plethora of research has identified a role for Notch signaling in diverse cellular processes such as differentiation, proliferation, apoptosis, adhesion, and epithelial-to-mesenchymal transition (EMT). This review focuses on Notch signaling during the development and progression of hematologic and solid malignancies, with emphasis on recent findings in these fields.
The Notch receptor family
The mammalian family of Notch receptors consists of four members: Notch1 through Notch4 ( Figure 1A ). Notch proteins are synthesized as full-length unprocessed proteins composed of extracellular, transmembrane, and intracellular domains. Following transport through the secretory pathway to the trans-Golgi network, Notch is cleaved at a site referred to as the S1 cleavage site by a furin-like convertase to generate two subunits: one consisting of the majority of the extracellular domain and the other consisting of the remainder of the extracellular domain and the complete transmembrane and intracellular domains 2 . These two subunits associate noncovalently resulting in the cell-surface expression of a mature heterodimeric Type I transmembrane receptor.
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Notch activation and signaling
The Notch ligand family consists of five members in mammals: Jagged1/2 and Delta-like Pen-2, and Aph-1 4 . Hence the Notch intracellular domain (NotchIC or NICD) is released into the cytoplasm, which subsequently translocates into the nucleus to effect Notch signaling.
Although Notch proteolytic processing at the S1 cleavage site does not result in Notch activation, processing at S2 and S3 cleavage sites is required for activation of the full-length Figure 2 . Ligand-mediated activation of Notch signaling. Notch expressed on the cell surface as a heterodimer is the mature, ligand-accessible form of the receptor. In the absence of ligand binding, heterodimeric Notch receptors are inactive. When Notch ligand binds to Notch receptor on an adjacent cell, a series of proteolytic cleavages occur (referred to as S2 and S3 cleavages), resulting in release of the Notch intracellular domain (NotchIC) that subsequently translocates into the nucleus. In the absence of nuclear NotchIC, the transcription factor CBF1 binds to the DNA sequence 5'-(C/T)GTGGGAA-3' within Notch target gene promoters and represses transcription. When Notch signaling is activated, nuclear NotchIC binds to CBF1 and, following recruitment of the nuclear protein MAML, results in the formation of a ternary complex that functions as a transcriptional activator. MAML recruits the histone acetyltransferase protein p300, resulting in histone acetylation and conversion of the local chromatin structure to a form amenable to active transcription, resulting in transcription of various Notch target genes including those belonging to the HES and HRT families. In humans, aberrant Notch1 expression has been identified as a causative factor in the development of T cell acute lymphoblastic leukemia and lymphoma (T-ALL) 29 . Analysis of patient samples has revealed a chromosomal translocation, t(7;9)(q34:q34.3), that juxtaposes the C-terminal domain of Notch1 adjacent to the T cell receptor-β locus 29 . This translocation results in the expression of a truncated constitutively-active Notch1, commonly referred to as translocation-associated Notch1 (TAN1) 29 . Lethally irradiated mice transplanted with bone marrow cells transduced with Notch1IC develop T-ALL with 100% penetrance 30 . Despite the ability of activated Notch1 to consistently induce T cell leukemia in mice, less than 1% of human T-ALL exhibit the t(7;9) translocation 31 . However, activating mutations in Notch1 independent of t(7;9) have been identified in more than 50% of human T-ALL 32 , with frequent occurrence in both childhood and adult cases of the disease 32, 33 . Activating mutations in Notch1 have since been reported in mouse models of T-ALL 34 . Thus deregulated Notch1 signaling plays a major role in the etiology of murine and human T-ALL. Activating mutations in Notch2 and Notch3 39 . In human B cell precursor ALL, Notch1 and HES1 mRNA expression is significantly lower than in T-ALL 40 . Indeed, a majority of B lymphoma cell lines exhibit intact Notch signaling that is precisely regulated 41 . Taken Deregulated Notch signaling is also involved in the pathogenesis of multiple myeloma.
Primary human multiple myeloma samples exhibit overexpression of Jagged1/2 and Notch1/2 only.
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Acute myelogenous leukemia (AML) is characterized by overexpression of Jagged1 mRNA/protein 40, 46 and Notch1 protein 46 . Aberrant Jagged1-Notch1 signaling is posited to promote the development of AML by inducing excessive self-renewal with a concomitant block in cell differentiation 40 . A recent study involving primary AML cells, however, has failed to demonstrate increased self-renewal in response to activated Notch signaling using recombinant Notch ligands 47 . Instead, ligand-mediated Notch activation is reported to promote AML cell differentiation 47 . Clearly additional studies are needed to elucidate the role of Notch signaling in AML pathogenesis.
Oncogenic Notch signaling in solid tumors
Similar to hematologic malignancies, expression of Notch pathway elements has been observed in solid human tumors. Although the vast majority of these studies demonstrate correlative associations between aberrant Notch ligand/receptor expression and tumor development, they nonetheless suggest a possible causative role for deregulated Notch signaling in solid tumor pathogenesis. Upregulation of Jagged1 mRNA and has been observed in human pancreatic cancer 48 , and Jagged1 protein overexpression has been reported in human cancers of the prostate 49 , cervix 50 , and brain 51, 52 . Jagged2 mRNA is upregulated in human cervical cancer 50 , with Jagged2 protein overexpression reported in human pancreatic cancer 48 . Dll1 expression is elevated in human cervical cancers at the mRNA level 50 and in human brain cancers at both mRNA and protein levels 52 .
Deregulated Notch receptor expression has been reported in a growing number of solid human tumors. Increased Notch1 protein expression has been observed in human cancers of the only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From cervix 50, 53 , colon 53 , lung 53 , pancreas 48 , skin 54 , and brain 51, 52 . Overexpression of Notch2 mRNA is observed in human brain cancer 55 , with Notch2 protein overexpression detected in human cancers of the cervix 50, 53 , colon 53 , pancreas 48 , skin 54 , and brain 51 . Protein overexpression of Notch3 and Notch4 has been reported in human malignant melanoma 54 and human pancreatic cancer 48 . A recent report has identified Notch4 mRNA expression in human breast cancer 18 . Amongst the many solid tumors exhibiting aberrant Notch expression, a causal role for Notch signaling in solid tumor pathogenesis has been best-studied in breast cancer models in mice.
The first study to identify a role for Notch signaling in murine mammary gland tumorigenesis came from observations of Czech II mice infected with Mouse Mammary Tumor Virus (MMTV) 56 . Of the mammary tumors that developed in these mice, 18% (9 of 45 tumors)
exhibited MMTV integration into the Notch4 locus. Of the tumors displaying MMTV integration into Notch4, all exhibited integration within a region of Notch4 that gives rise to a truncated protein consisting primarily of a constitutively-active form encoding the transmembrane and intracellular domains. Similar to MMTV, intracisternal A particle integration into the Notch4 locus also results in expression of a constitutively-active Notch4, and has been observed in spontaneous mammary tumors in both Czech II 57 and Balb/c mouse strains 58 . These studies clearly link aberrant Notch4 signaling to murine mammary gland tumorigenesis.
To directly demonstrate that activated Notch4 signaling is oncogenic in the murine mammary gland, activated Notch alleles have been introduced into mice. Transgenic mice expressing activated Notch4 under the control of the MMTV long terminal repeat or the whey acidic protein promoter develop mammary carcinomas with subsequent metastasis to the lungs [59] [60] [61] . A role for Notch1 in murine mammary tumorigenesis has also been reported. c-ErbB2 65 . In a second study involving 25 specimens, mRNAs for all four Notch receptors were expressed at varying frequencies 18 . A third study involving 97 specimens demonstrated that poorly-differentiated breast tumors were associated with elevated levels of Notch1 protein and reduced patient survival 66 . More importantly, a recent study has shown that greater than 50% of human breast tumors express reduced protein levels of Numb, a negative regulator of Notch signaling, and a negative correlation exists between Numb expression and breast tumor grade 67 . Taken together, these findings suggest an oncogenic role for Notch signaling in human breast cancer and a potential tumor suppressive function for Numb in this disease. and Bcl2 families, as well as FLICE-like inhibitor protein (FLIP) 69, 70 . Recently, Notch signaling has been shown to promote the survival of pre-T cells through the maintenance of cell size, as well as through the promotion of glucose uptake and metabolism 71 . Importantly, Notch promotes pre-T cell viability by signaling through the phosphatidylinositol 3-kinase (PI3K) pathway 71 . Notch can also protect against apoptosis by suppressing expression of the tumor suppressor p53, which in turn may promote T cell lymphomagenesis 72 . only.
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Several other players involved in Notch-induced T cell neoplastic transformation have been identified. Induction of T-ALL by activated Notch1/3 requires signaling through the pre-T cell receptor (pre-TCR), which promotes pre-T cell proliferation and survival 73, 74 . In the absence of genes required for pre-TCR assembly, such as pre-Tα, Notch1IC-induced T-ALL is prevented 73 . In fact, pre-Tα may be a direct target gene of Notch 75 . Molecules involved in the development of hematologic malignancies other than T-ALL are only now being elucidated. In B-CLL, expression of the transmembrane glycoprotein CD23a
is associated with enhanced cell survival. Notch2 activation promotes B-CLL cell survival by upregulating CD23a expression 80 . In multiple myeloma, overexpression of activated Notch1
upregulates the cyclin-dependent kinase inhibitor p21 Cip1 , resulting in cell cycle arrest and a concomitant protection from drug-induced apoptosis 81 . Evidence suggests that Jagged2 only.
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For Increased cell proliferation in response to Notch activation may also promote tumorigenesis. In a kidney epithelial cell line, activated Notch1 promotes cell cycle entry by enhancing CDK2 and cyclin D1 activity, the latter of which may be a direct target of Notch 90 . In HeLa cells, HES1 promotes cell proliferation by repressing transcription of the cyclin-dependent kinase inhibitor p27 Kip1 91 . In 3T3 fibroblasts, Notch signaling attenuates p27 Kip1 expression by a mechanism independent of transcriptional repression. Specifically, activated Notch1 induces expression of the S phase kinase-associated protein 2 (SKP2), a subunit of the ubiquitin-ligase complex SCF SKP2 , which in turn enhances proteasome-mediated degradation of p27 Kip1 92 . The fact that SKP2 also promotes degradation of p21 Cip1 further enhances the ability of Notch to promote cell cycle entry 92 .
The transforming ability of Notch may also be mediated through activated Ras signaling. 
Notch activation can be tumor suppressive
Despite mounting evidence demonstrating an oncogenic role for activated Notch signaling in hematologic and solid malignancies, a re-evaluation of the tumor-promoting function of Notch was necessary with the discovery that Notch signaling could be tumor suppressive.
Tumor suppressive Notch signaling in hematologic malignancies
Simultaneous activation of Notch1 and inactivation of Notch2 may play a role in T cell lymphomagenesis. Specifically, γ-radiation-induced mouse thymic lymphomas exhibit overexpression of Notch1 mRNA and reduced Notch2 mRNA 108 . Because activating mutations in Notch2 can induce T-ALL 35 , additional studies are needed to clarify the role of Notch2 in T cell malignancies. 
Tumor suppressive Notch signaling in solid tumors
In human cervical cancers, early disease stage specimens exhibit enhanced Notch1 protein expression, whereas late stage cervical cancers express reduced Notch1 protein levels 113 .
Because expression of activated Notch1 causes strong growth inhibition of HPV-positive cervical carcinoma cells, downregulation of Notch1 in late stage cervical cancer is posited to play a role in the maintenance of malignant transformation 113 . Hence Notch1 expression in early stage cervical cancer may promote tumor formation whereas expression in late stage cervical cancer may be tumor suppressive.
A tumor suppressive function for Notch1 has also been demonstrated in mouse skin.
When Notch1 function is inactivated specifically in mouse skin, the epidermis undergoes hyperproliferation with subsequent development of skin tumors 114 . These mice also have increased sensitivity to chemical-induced skin carcinogenesis 114 . Recent findings suggest that Notch1 may function as a tumor suppressor in human skin as well. In normal differentiated only.
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A tumor suppressive role for activated Notch signaling has also been suggested in the prostate 116 , lung 117 , brain 55 , and liver 118 .
Preliminary studies of human breast cancer specimens suggest a possible tumor suppressive role for Notch2. In contrast to poorly-differentiated breast tumors, welldifferentiated breast tumors are associated with elevated levels of Notch2 protein and increased patient survival 66 . Interestingly, poorly-differentiated breast tumors exhibit elevated levels of Notch1 protein and reduced patient survival 66 . These findings suggest that in human breast cancer, Notch1 may be oncogenic whereas Notch2 may be tumor suppressive.
Molecular and functional basis of Notch-induced tumor suppression
Because the tumor suppressive function of Notch is a relatively new concept, the molecular mechanisms involved in this process have not been adequately elucidated.
Nonetheless, several studies have highlighted anti-proliferative effects of Notch signaling as an important mechanism ( Figure 5 ). In small-cell lung cancer cell lines, expression of activated Notch1 or Notch2 has been shown to upregulate the expression of p21 Cip1 and p27 Kip1 , resulting in cell cycle arrest 117 . In mouse keratinocytes, activated Notch1 signaling upregulates p21
Cip1 which in turn induces cell cycle arrest 119 . This cessation of proliferation is necessary for terminal differentiation of the keratinocyte to occur. Accordingly, mice with targeted disruption of Notch1 in the epidermis develop skin tumors with decreased p21 Cip1 levels 114 . These mice also exhibit enhanced β-catenin signaling 114 . Given that enforced expression of constitutively-active Notch1 in mouse keratinocytes inhibits β-catenin signaling 114 , these results suggest that Notch1 signaling prevents tumorigenesis in normal mouse skin by blocking proliferation through at least only.
For Cip1 , which in turn associates with the E2F-1 transcription factor at the Wnt4 promoter 120 . This association blocks the recruitment of c-Myc and p300, resulting in transcriptional repression of Wnt4 expression and hence attenuated Wnt signaling 120 . Additional studies are needed to determine whether similar mechanisms occur during Notch-mediated tumor suppression in human keratinocytes.
The role of Notch in regulating angiogenesis
It is well known that signaling pathways involved in physiological angiogenesis are commonly exploited during the induction of tumor angiogenesis. Evidence has emerged in support of a role for Notch signaling in modeling and maintaining the vasculature 19 .
Importantly, these findings highlight a potential role for deregulated Notch signaling in tumor angiogenesis and metastasis.
Notch activation regulates angiogenesis The first evidence that activated Notch signaling could inhibit blood vessel development came from a study involving transgenic mice engineered to express activated Notch4 specifically in the mouse embryonic vasculature. These mice display vascular patterning defects consistent with attenuated vascular development 121 . In an in vitro assay in which human endothelial cells coated on beads are stimulated to migrate into a three-dimensional fibrin gel, expression of activated Notch4 inhibits spontaneous endothelial sprouting, as well as sprouting in response to fibroblast growth factor 2 (FGF2) and vascular endothelial growth factor (VEGF) 122 . In an in These findings suggest that Notch4 activation in endothelial cells, via a mechanism involving signaling mediated by the cdc10/ankyrin repeats, may inhibit angiogenesis by promoting β1
integrin-mediated adhesion to the underlying matrix, thereby preventing migration and effectively fixing the cells in place.
Attenuation of endothelial cell proliferation may also play a role in Notch-inhibited endothelial sprouting. It has been postulated that low or absent HRT1 expression may be permissive to endothelial proliferation whereas overexpression of HRT1 may block this process, thus inhibiting the formation of new endothelial tubes 129 . Recent evidence has confirmed an only. 
Discussion and conclusions
In efforts to elucidate the molecular mechanisms involved in cancer development, it is becoming increasingly important to identify the cellular factors that determine whether Notch signaling will be oncogenic or tumor suppressive. Several factors may play a role in determining whether Notch acts to promote or suppress tumorigenesis. One factor is the specific Notch paralog activated. In human breast cancer, Notch1 is often associated with oncogenesis whereas Notch2 may be associated with tumor suppression 66 . In contrast, in human brain tumors, Notch1 may be tumor suppressive with Notch2 playing an oncogenic role 55 . Because most cancers express more than one type of Notch ligand and/or receptor, the overall expression profile of these ligands/receptors may ultimately determine whether Notch signaling will be oncogenic or oncosuppressive. with an associated inhibition of proliferation 126 . Notch activation can also inhibit or promote apoptosis, depending on the cell type. For example, Notch activation in Kaposi's sarcoma cells inhibits apoptosis whereas in hepatocellular carcinoma cells Notch promotes cell death 131, 132 .
A third factor is the presence of specific cytokines/growth factors in the cellular microenvironment. Notch activation in the presence of macrophage colony-stimulating factor, but not granulocyte-macrophage colony-stimulating factor (GM-CSF), induces apoptosis in monocytes 24 . Interestingly, Notch activation in the presence of GM-CSF inhibits the differentiation of monocytes into macrophages, but permits their differentiation into mature dendritic cells in the presence of GM-CSF, interleukin-4, and tumor necrosis factor-α 133 .
Moreover, Notch activation in the presence of both GM-CSF and TGFβ1 promotes monocyte differentiation into Langerhans cells 134 .
A fourth factor is the dosage of Notch signaling. In a leukemic T cell line, low or high concentrations of Notch1IC promote or inhibit NFκB transactivation, respectively 135 . In cord blood progenitor cells, ex vivo culture with low density of immobilized Dll1 promotes the survival of CD34 + cells, while a high concentration of Dll1-induced Notch activation inhibits the generation/survival of CD34 + cells 136 . Similarly, the level of Notch signaling within the thymic microenvironment can determine the differentiation fate of hematopoietic precursor cells 137 . 
